West Pharmaceutical Services Stock Net Asset
WST Stock | USD 316.59 4.29 1.34% |
West Pharmaceutical Services fundamentals help investors to digest information that contributes to West Pharmaceutical's financial success or failures. It also enables traders to predict the movement of West Stock. The fundamental analysis module provides a way to measure West Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to West Pharmaceutical stock.
West | Net Asset |
West Pharmaceutical Services Company Net Asset Analysis
West Pharmaceutical's Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current West Pharmaceutical Net Asset | 3.83 B |
Most of West Pharmaceutical's fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, West Pharmaceutical Services is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
West Net Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for West Pharmaceutical is extremely important. It helps to project a fair market value of West Stock properly, considering its historical fundamentals such as Net Asset. Since West Pharmaceutical's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of West Pharmaceutical's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of West Pharmaceutical's interrelated accounts and indicators.
Click cells to compare fundamentals
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
Competition |
West Total Assets
Total Assets |
|
Based on the recorded statements, West Pharmaceutical Services has a Net Asset of 3.83 B. This is much higher than that of the Health Care Equipment & Supplies sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
West Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses West Pharmaceutical's direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of West Pharmaceutical could also be used in its relative valuation, which is a method of valuing West Pharmaceutical by comparing valuation metrics of similar companies.West Pharmaceutical is currently under evaluation in net asset category among its peers.
West Pharmaceutical ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, West Pharmaceutical's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to West Pharmaceutical's managers, analysts, and investors.Environmental | Governance | Social |
West Pharmaceutical Institutional Holders
Institutional Holdings refers to the ownership stake in West Pharmaceutical that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of West Pharmaceutical's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing West Pharmaceutical's value.Shares | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.3 M | Proshare Advisors Llc | 2024-09-30 | 1.1 M | Durable Capital Partners Lp | 2024-09-30 | 1.1 M | Jpmorgan Chase & Co | 2024-06-30 | 909.1 K | Norges Bank | 2024-06-30 | 866.4 K | T. Rowe Price Investment Management,inc. | 2024-09-30 | 839.3 K | Findlay Park Partners Llp | 2024-09-30 | 827.7 K | Ubs Asset Mgmt Americas Inc | 2024-09-30 | 683.4 K | Northern Trust Corp | 2024-09-30 | 659.4 K | Vanguard Group Inc | 2024-09-30 | 9 M | Blackrock Inc | 2024-06-30 | 7.6 M |
West Fundamentals
Return On Equity | 0.18 | ||||
Return On Asset | 0.1 | ||||
Profit Margin | 0.17 % | ||||
Operating Margin | 0.22 % | ||||
Current Valuation | 22.74 B | ||||
Shares Outstanding | 72.42 M | ||||
Shares Owned By Insiders | 0.58 % | ||||
Shares Owned By Institutions | 96.69 % | ||||
Number Of Shares Shorted | 1.43 M | ||||
Price To Earning | 40.71 X | ||||
Price To Book | 8.33 X | ||||
Price To Sales | 7.97 X | ||||
Revenue | 2.95 B | ||||
Gross Profit | 1.14 B | ||||
EBITDA | 847.8 M | ||||
Net Income | 593.4 M | ||||
Cash And Equivalents | 894.3 M | ||||
Cash Per Share | 9.85 X | ||||
Total Debt | 309 M | ||||
Debt To Equity | 0.12 % | ||||
Current Ratio | 3.80 X | ||||
Book Value Per Share | 37.96 X | ||||
Cash Flow From Operations | 776.5 M | ||||
Short Ratio | 1.83 X | ||||
Earnings Per Share | 6.74 X | ||||
Price To Earnings To Growth | 5.91 X | ||||
Target Price | 361.57 | ||||
Number Of Employees | 10.6 K | ||||
Beta | 1.0 | ||||
Market Capitalization | 22.93 B | ||||
Total Asset | 3.83 B | ||||
Retained Earnings | 3.52 B | ||||
Working Capital | 1.26 B | ||||
Current Asset | 673.7 M | ||||
Current Liabilities | 314.3 M | ||||
Annual Yield | 0 % | ||||
Five Year Return | 0.36 % | ||||
Net Asset | 3.83 B | ||||
Last Dividend Paid | 0.8 |
About West Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze West Pharmaceutical Services's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of West Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of West Pharmaceutical Services based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for West Stock Analysis
When running West Pharmaceutical's price analysis, check to measure West Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy West Pharmaceutical is operating at the current time. Most of West Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of West Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move West Pharmaceutical's price. Additionally, you may evaluate how the addition of West Pharmaceutical to your portfolios can decrease your overall portfolio volatility.